Suppr超能文献

在线血液透析滤过过程中治疗浓度下的万古霉素。

Subtherapeutic serum vancomycin concentrations during on-line hemodiafiltration.

机构信息

Renal Unit, G. H. "G. Papanikolaou," Thessaloniki, Greece.

出版信息

ASAIO J. 2011 Nov-Dec;57(6):507-10. doi: 10.1097/MAT.0b013e3182306196.

Abstract

The aim of the study is to study vancomycin serum concentration changes during on-line hemodiafiltration (OL-HDF) and determine whether administration of vancomycin during the last hour of OL-HDF provides therapeutic serum concentrations. Vancomycin was administered intravenously at a dose of 15 mg/kg to 17 chronic hemodialysis patients who were enrolled into two study groups (A and B). In group A patients (n = 11), vancomycin was administered immediately postdialysis. Forty-three hours later, a 4-hour OL-HDF session was performed. Blood samples (S) for vancomycin measurement were drawn before, during, and after the session. In group B patients (n = 6), vancomycin was administered during the last hour of a 4-hour OL-HDF session on Monday. Vancomycin serum concentrations were measured postdialysis, as well as before and after the next two dialysis sessions of the week. In group A patients, mean vancomycin concentrations were reduced by 50% (S(pre): 10.2 ± 1.4 μg/ml, S(post): 5.0 ± 0.9 μg/ml). Vancomycin dialysance was 74.6 ± 29.3 ml/min, while the volume of distribution was 0.42 L/kg. In group B patients, mean vancomycin concentrations before the beginning of Wednesday and Friday dialysis sessions were 3.1 ± 0.7 and 1.4 ± 0.4 μg/ml, respectively. Postdialysis administration of vancomycin followed by OL-HDF resulted in a 50% reduction of vancomycin serum concentrations. Administration during the last treatment hour of OL-HDF results in subtherapeutic vancomycin serum concentrations over the course of the subsequent inter- and intradialytic intervals.

摘要

本研究旨在研究在线血液透析滤过(OL-HDF)过程中万古霉素血清浓度的变化,并确定在 OL-HDF 的最后 1 小时内给予万古霉素是否能提供治疗性的血清浓度。17 例慢性血液透析患者被纳入两个研究组(A 组和 B 组),分别静脉给予 15mg/kg 的万古霉素。在 A 组患者(n=11)中,万古霉素在透析后立即给予。43 小时后,进行了 4 小时的 OL-HDF 治疗。在治疗前、治疗中和治疗后采集血样(S)以测量万古霉素。在 B 组患者(n=6)中,万古霉素在周一的 4 小时 OL-HDF 治疗的最后 1 小时内给予。在透析后,以及本周的随后两次透析治疗前和后测量万古霉素血清浓度。在 A 组患者中,万古霉素的平均浓度降低了 50%(S(pre):10.2±1.4μg/ml,S(post):5.0±0.9μg/ml)。万古霉素透析清除率为 74.6±29.3ml/min,分布容积为 0.42L/kg。在 B 组患者中,星期三和星期五透析治疗开始前的万古霉素平均浓度分别为 3.1±0.7μg/ml 和 1.4±0.4μg/ml。OL-HDF 治疗后给予万古霉素,可使万古霉素血清浓度降低 50%。在 OL-HDF 的最后治疗时间内给予万古霉素,会导致随后的透析内和透析间间隔内出现治疗性的万古霉素血清浓度降低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验